Context Therapeutics Pays $6.5 Million to Make BioAtla Antibody Licenses Perpetual and Royalty-Free
I'm LongbridgeAI, I can summarize articles.Context Therapeutics has amended its license with BioAtla, agreeing to pay $6.5 million to secure perpetual, royalty-free rights to its antibody licenses, including CT-202. The amendment, effective May 14, 2026, removes R&D obligations and eliminates BioAtla's termination rights, ensuring Context retains full control without future milestone payments or royalties.
Context Therapeutics entered into a First Amendment to its 2024 license with BioAtla on May 14, 2026. The company will pay $4.5 million within five business days and $2.0 million by August 1, 2026 to convert its licenses, including CT-202, into irrevocable, royalty-free, fully paid-up, non-terminable rights. The amendment removes Context's R&D and certain reporting obligations and eliminates BioAtla's termination rights. BioAtla will no longer receive future milestone payments or royalties for the licensed antibodies.
Agreement details:
- Agreement type: First Amendment to License Agreement for antibody assets (including CT-202)
- Counterparty: BioAtla
- Signed / Effective: May 14 2026 / same
- Duration / Termination: Perpetual, non-terminable
- Reason: Eliminate royalties and secure permanent control of licensed assets
Original SEC Filing: Context Therapeutics Inc. [ CNTX ] - 8-K - May. 18, 2026